| Volume 26, 2022 Articles |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
PreScription: IJPC--Starting Year 26
Allen Loyd V Jr
|
Jan/Feb 2022
Pg. 4
|
Compounded Melatonin Cream for the Prevention and Treatment of Radiation Dermatitis: A Case Report
Garcia-Segura Laura Corral, Garcia-Segura Javier Corral, Delgado Carlos Dorado, Maldonaldo Nuria Romero, Salgado Elena Cardero, Llorens Lucía Pérez
|
Jan/Feb 2022
Pg. 6-8
|
Pharmacy Student Satisfaction and Perceptions Following a Virtual Sterile Compounding Experience
Mohammad Insaf, Lobkovich Alison, Nardolillo Joseph, Wilhelm Shelia
|
Jan/Feb 2022
Pg. 10-17
|
A Compendium of Compounding Agents and Formulations, Part 1: Melatonin
Riepl Mike
|
Jan/Feb 2022
Pg. 18-23
|
Editorial: Should All Pharmacists Compound?
Allen Loyd V Jr
|
Jan/Feb 2022
Pg. 24-28
|
Everything Old is New Again
Brunner Scott
|
Jan/Feb 2022
Pg. 30-32
|
Basics: Considerations and Background Information for Counseling Patients Using Compounded Suppositories
Allen Loyd V Jr
|
Jan/Feb 2022
Pg. 34-38
|
Sterile Basics: Compounding Sterile Preparations with Cyclodextrins
Allen Loyd V Jr
|
Jan/Feb 2022
Pg. 41-49
|
Calculations
Stockton Shelly J
|
Jan/Feb 2022
Pg. 50
|
Aluminum Chloride 6.25% in Anhydrous Alcohol
Allen Loyd V Jr
|
Jan/Feb 2022
Pg. 52
|
Ascorbic Acid 10% in Anhydrous PEG ointment
Allen Loyd V Jr
|
Jan/Feb 2022
Pg. 53
|
Deoxyarbutin 3% Anhydrous Emulsion
Allen Loyd V Jr
|
Jan/Feb 2022
Pg. 54
|
Diclofenac Sodium 1%-15% Topical Gel
Allen Loyd V Jr
|
Jan/Feb 2022
Pg. 55
|
Enalapril Maleate 1 mg-mL in Ora-Plus and Ora-Sweet Suspension
Allen Loyd V Jr
|
Jan/Feb 2022
Pg. 56
|
Mometasone Furoate 0.1% Lotion
Allen Loyd V Jr
|
Jan/Feb 2022
Pg. 57
|
Capsule Machine Validation
Al-Achi Antoine, McGreggor Tysheon, Jaligama Shreelekha, Friday Kafi, Alyami Hussain
|
Jan/Feb 2022
Pg. 58-64
|
Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Hong Eun Ji, Sumanasekera Wasana, Le Uyen Minh
|
Jan/Feb 2022
Pg. 65-71
|
Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding (Reprint)
Soefje Scott, Rickabaugh Keith, Rajkumar Rahul, Wall Kathryn P
|
Jan/Feb 2022
Pg. 72-79
|
Investigation of the Effects of Excipients in the Compounding of Amlodipine Besylate Orally Disintegrating Tablets
Azmi Nurual Hanisah Saiful, Ming Long Chiau, Uddin A.B.M. Helal, Sarker Zaidul Islam, Bin Liew Kai
|
Jan/Feb 2022
Pg. 80-87
|
PreScription: Comments on the FDA Guidance "Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry"
Allen Loyd V Jr
|
Mar/Apr 2022
Pg. 92
|
A Compendium of Compounding Agents and Formulations, Part 2: Metronidazole, Misoprostol, and Phenytoin
Riepl Mike
|
Mar/Apr 2022
Pg. 94-98
|
Allowing Compounding Pharmacies to Address Drug Shortages
Broughel James
|
Mar/Apr 2022
Pg. 100-109
|
The Potential Effects of a Compounded Methylcobalamin Nasal Spray on Short-term Memory Loss After Intracranial Hemorrhage: A Case Report
Good Lauren, Lieu Yi, Banov Fabiana, Harger Beau, Banov Daniel
|
Mar/Apr 2022
Pg. 110-115
|
Quality Control: Photodocumentation in Pharmacy Compounding
Allen Loyd V Jr
|
Mar/Apr 2022
Pg. 116-117
|
Basics of Compounding: Compounding Nonsterile Preparations Using Cyclodextrins
Allen Loyd V Jr
|
Mar/Apr 2022
Pg. 118-126
|
Sterile Basics of Compounding: Methods of Sterilization and Depyrogenation
Allen Loyd V Jr
|
Mar/Apr 2022
Pg. 129-136
|
Calculations
Stockton Shelly J
|
Mar/Apr 2022
Pg. 138
|
Alprazolam 1 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Mar/Apr 2022
Pg. 140
|
Codeine Phosphate 3 mg/mL in Ora-Sweet
Allen Loyd V Jr
|
Mar/Apr 2022
Pg. 141
|
Ketoconazole 2%, Terbenafine 1%, Acetic Acid 2%, and Urea 2% in Dimethyl Sulfoxide Nail Polish
Allen Loyd V Jr
|
Mar/Apr 2022
Pg. 142
|
Lorazepam 1 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Mar/Apr 2022
Pg. 143
|
Mesalamine 100-mg/mL Suspension Enema
Allen Loyd V Jr
|
Mar/Apr 2022
Pg. 144
|
Naproxen 25 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Mar/Apr 2022
Pg. 145
|
Phenobarbital 10 mg/mL in SyrSpend SF pH4, Cherry Flavored
Allen Loyd V Jr
|
Mar/Apr 2022
Pg. 146
|
Phenytoin 15 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Mar/Apr 2022
Pg. 147
|
Propranolol 2 mg/mL and 5 mg/mL in Ora-Blend SF Suspension
Allen Loyd V Jr
|
Mar/Apr 2022
Pg. 148
|
Pyridoxine Hydrochloride 50 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Mar/Apr 2022
Pg. 149
|
Stability Studies of Fludrocortisone Acetate Capsules and Fludrocortisone Acetate Titrated Powders (Powder Triturates)
Brandin Thibaut, Wasilewski Maya, Panuccio Camille, Bouguergour Cyrielle, Primas Nicolas, Lamy Edouard, Jean Christophe, Bertault-Peres Pierre, Rathelot Pascal, Curti Christophe, Vanelle Patrice
|
Mar/Apr 2022
Pg. 150-154
|
Comparison of Solvent Casting and Spray Casting Method on Compounding of an Orally Disintegrating Film Containing Amlodipine Besylate
Ruslan Mohamad Fariz Haiqal, Janakiraman Ashok Kumar, Ming Long Chiau, Uddin ABM Helal, Sarker Zaidul Islam, Bin Liew Kai
|
Mar/Apr 2022
Pg. 155-162
|
Molding as Innovative Technology for Personalized Tablet Production
Mady Omar Y, Al-Shoubki Adam A, Hagag Youssef, Ibrahim Bakry, Donia Ahmed A
|
Mar/Apr 2022
Pg. 163-174
|
PreScription: Standing in the Gap
Allen Loyd V Jr
|
May/Jun 2022
Pg. 180
|
Art of Pharmacy v. State
Standridge Rob
|
May/Jun 2022
Pg. 182-186
|
A Compendium of Compounding Agents and Formulations, Part 3: Gentamicin Sulfate and Benzoyl Peroxide
Riepl Mike
|
May/Jun 2022
Pg. 189-193
|
A Procedure for Tablet Production by Using the 3D Molding Technology and Powder Micromeritics Properties
Mady Omar
|
May/Jun 2022
Pg. 195-200
|
Compounding for Investigational and Clinical Studies
Allen Loyd V Jr
|
May/Jun 2022
Pg. 201-209
|
Three Things You Need to Know Right Now
Brunner Scott
|
May/Jun 2022
Pg. 211-213
|
Basics of Compounding: Vehicle for Drug Administration via Enteral Feeding Tubes
Allen Loyd V Jr
|
May/Jun 2022
Pg. 214-217
|
Sterile Basics of Compounding: Particulates in Parenteral Preparations: Sources, Minimization, and Detection
Allen Loyd V Jr
|
May/Jun 2022
Pg. 219-228
|
Calculations
Stockton Shelly J
|
May/Jun 2022
Pg. 230
|
Alendronate Sodium 1% Topical Dental Gel
Allen Loyd V Jr
|
May/Jun 2022
Pg. 232
|
Azstarys in Ora-Blend Single Dose
Allen Loyd V Jr
|
May/Jun 2022
Pg. 233
|
Candesartan Cilexitil 1 mg/mL Syrup
Allen Loyd V Jr
|
May/Jun 2022
Pg. 234
|
Chloral Hydrate 70 mg/mL Syrup
Allen Loyd V Jr
|
May/Jun 2022
Pg. 235
|
Cinnarizine 1 mg/mL in Oral Medium-Chain Triglycerides Anhydrous Vehicle
Allen Loyd V Jr
|
May/Jun 2022
Pg. 236
|
Clobazam 1 mg/mL in Oral-Mix Suspension
Allen Loyd V Jr
|
May/Jun 2022
Pg. 237
|
Metronidazole 7.5 mg/mL Topical Oil-in-Water Microemulsion
Allen Loyd V Jr
|
May/Jun 2022
Pg. 238
|
Nitrazepam 1 mg/mL Oral Solution
Allen Loyd V Jr
|
May/Jun 2022
Pg. 239
|
Sirolimus 0.1% Ointment
Allen Loyd V Jr
|
May/Jun 2022
Pg. 240
|
Valganciclovir 20 mg/mL in Ora-Plus and Ora-Sweet Suspension
Allen Loyd V Jr
|
May/Jun 2022
Pg. 241
|
Finding the Right Balance: A Nationwide Study of Student Pharmacist Exposure to and Perceptions of Nonsterile Compounding
Fredrickson Mary E, Belcher Faith G, Del Vecchio Kamryn N, Galleher Miranda N, Jugo Leila S, Gothard M David, Pallotta Raneem H, Pallotta Victor A Jr
|
May/Jun 2022
Pg. 242-247
|
Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine
Catry Emilie, Colsoul Marie-Louise, Closset Melanie, Hubert Justine, Soumoy Laura, Bihin Benoit, Thiry Emmanuell, Jamart Jacques, Hecq Jean-Daniel, Galanti Laurence
|
May/Jun 2022
Pg. 248-254
|
Application of Co-processed Excipient as a Novel Method to Compound Orally Disintegrating Tablets
Liew Kai Bin, Hii Shou Hui, Chew Yik Ling, Ming Long Chiau, Uddin ABM Helal, Sarker Zaidul Islam
|
May/Jun 2022
Pg. 255-263
|
PreScription: Pharmacy and Drug Information
Allen Loyd V Jr
|
Jul/Aug 2022
Pg. 268
|
A Compendium of Compounding Agents and Formulations, Part 4: Nifedipine and Pentoxifylline
Riepl Mike
|
Jul/Aug 2022
Pg. 270-274
|
Compounding with Pracaxi Versus Copaiba Oil
Magutu Tom
|
Jul/Aug 2022
Pg. 277-281
|
Evaluation of the Physical-chemical Characteristics and Biopharmaceutical Performance of Dilu-Cap: A Complete Line of Excipients for Hard-shell Capsules
de Oliveira Ferreira Anderson, Polonini Hudson
|
Jul/Aug 2022
Pg. 283-291
|
Compounding for Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases
Harrington Amy, Williams LaVonn
|
Jul/Aug 2022
Pg. 293-296
|
The Role of Compounding Pharmacists During Drug Shortages
Ofei Kelvin
|
Jul/Aug 2022
Pg. 298-301
|
Basics: Hollow-type Suppositories
Allen Loyd V Jr
|
Jul/Aug 2022
Pg. 302-307
|
Sterile Basics of Compounding: How to Implement a Robust Visual-inspection Program
Summers Amy
|
Jul/Aug 2022
Pg. 309-315
|
Calculations
Stockton Shelly J
|
Jul/Aug 2022
Pg. 316
|
Betamethasone Dipropionate 0.05% and Salicylic Acid 3% Lotion
Allen Loyd V Jr
|
Jul/Aug 2022
Pg. 318
|
Cetrimide Lotion
Allen Loyd V Jr
|
Jul/Aug 2022
Pg. 319
|
Dexamethasone 1 mg/mL in Oral Mix
Allen Loyd V Jr
|
Jul/Aug 2022
Pg. 320
|
Furosemide 5-mg/mL Oral Suspension
Allen Loyd V Jr
|
Jul/Aug 2022
Pg. 321-322
|
Hydralazine Hydrochloride 10 mg/mL Oral Liquid
Allen Loyd V Jr
|
Jul/Aug 2022
Pg. 323-324
|
Indomethacin 1% Topical Gel
Allen Loyd V Jr
|
Jul/Aug 2022
Pg. 325-326
|
Nystatin 250,000-unit Frozen Popsicles
Allen Loyd V Jr
|
Jul/Aug 2022
Pg. 327
|
Povidone Iodine 100-mg/mL Solution/Spray
Allen Loyd V Jr
|
Jul/Aug 2022
Pg. 328
|
Psoriasis Topical Ointment
Allen Loyd V Jr
|
Jul/Aug 2022
Pg. 329
|
Physicochemical and Microbiological Stability of Vancomycin 10-mg/mL Intravitreal Syringes
Bartoll Aaron Puplà, Bellés Medall Maria Dolores, Peñarrocha Josep Edo, Escrig Laura Solaz, Clemente Ruben Eguren, Azuara Julia Bodega, Piqueres Raul Ferrando
|
Jul/Aug 2022
Pg. 330-335
|
Long-term Stability of Epitheliotropic Factors in Frozen Serum Eye Drops
Sahyoun Jean-Yves, Cloutier Marc, Frenette Mathieu, Robert Marie-Claude
|
Jul/Aug 2022
Pg. 336-341
|
Physicochemical and Microbiological Stability of Amitriptyline Hydrochloride Oral Liquid Dosage Forms in PCCA Base, SuspendIt
Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Kader Cyndy, Morris Tommy C, Graves Richard A
|
Jul/Aug 2022
Pg. 342-351
|
PreScription: A New Dosage Form
Allen Loyd V Jr
|
Sep/Oct 2022
Pg. 356
|
Hazardous Drug Enteral Device: A Closed System Device for Crushing and Dispersing Hazardous Drug Tablets for Enteral Administration
Lopez C Vidal, Rios GL Quito
|
Sep/Oct 2022
Pg. 358-362
|
A Compendium of Compounding Agents and Formulations, Part 5: Timolol and Beta-glucans
Riepl Mike
|
Sep/Oct 2022
Pg. 364-368
|
Recent Formulation Advances and Preparation of Orally Disintegrating Tablets
Ejeta Fikadu
|
Sep/Oct 2022
Pg. 370-377
|
Compounded Medications and Probiotics for Irritable Bowel Syndrome
Narváez Katherine Rivera, Thompson Tara
|
Sep/Oct 2022
Pg. 378-384
|
Compounding with Biotechnology Products, Part 1: General Considerations
Allen Loyd V Jr
|
Sep/Oct 2022
Pg. 385-395
|
The FDA is in a Hole. It Should Stop Digging.
Brunner Scott
|
Sep/Oct 2022
Pg. 396-398
|
Basics of Compounding: Compounding with Microneedle Arrays, Part 1: Introduction and Overview
Allen Loyd V Jr
|
Sep/Oct 2022
Pg. 400-408
|
Sterile Basics of Compounding: Contamination Control Strategies, Part 1
Summers Amy
|
Sep/Oct 2022
Pg. 411-418
|
Calculations
Stockton Shelly J
|
Sep/Oct 2022
Pg. 420
|
Amphotericin B 3% Otic Gel
Allen Loyd V Jr
|
Sep/Oct 2022
Pg. 422
|
Ascorbic acid 5% Topical Microemulsion
Allen Loyd V Jr
|
Sep/Oct 2022
Pg. 423
|
Chlorhexidine Diacetate 2% Topical Gel
Allen Loyd V Jr
|
Sep/Oct 2022
Pg. 424
|
Clindamycin Hydrochloride 10-mg/mL Oral Suspension
Allen Loyd V Jr
|
Sep/Oct 2022
Pg. 425
|
Clotrimazole 10-mg Troches
Allen Loyd V Jr
|
Sep/Oct 2022
Pg. 426
|
Cysteamine Hydrochloride 100 mg/mL Oral Solution
Allen Loyd V Jr
|
Sep/Oct 2022
Pg. 427
|
Hydrogen Peroxide 1.5% with Sodium Fluoride 0.5-mg/mL Oral Rinse
Allen Loyd V Jr
|
Sep/Oct 2022
Pg. 428
|
Lansoprazole 3-mg/mL in Ora-Blend Suspension
Allen Loyd V Jr
|
Sep/Oct 2022
Pg. 429
|
Metronidazole 10%, Nifedipine 0.5%, Lidocaine 1.5%, and Diclofenac 3% Ointment
Allen Loyd V Jr
|
Sep/Oct 2022
Pg. 430
|
Methylcobalamin 2-mg/mL Nasal Spray
Allen Loyd V Jr
|
Sep/Oct 2022
Pg. 431
|
Effectiveness of a New Ultraviolet C Disinfection System to Inactivate Airborne Coronavirus in Different Environmental Conditions
Marianni Bruna, Polonini Hudson
|
Sep/Oct 2022
Pg. 432-435
|
Effects of Calcium Polystyrene Sulfonate Formulation Change from Dry Syrup to Oral Solution in Patients with Chronic Kidney Disease
Kobayashi Shunsuke, Ogawara Yuka, Imamura Yoshihiko, Kitaoka Akira, Yasu Takeo
|
Sep/Oct 2022
Pg. 436-439
|
PreScription: Compounded Drugs Often Become Manufactured Drugs
Allen Loyd V Jr
|
Nov/Dec 2022
Pg. 444
|
Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Allen Loyd V Jr
|
Nov/Dec 2022
Pg. 446-466
|
Unlicensed Transdermal Medications in Feline Patients: Three Case Reports
Urwin Craig, Jean Linda, Carvalho Maria, Robson-Laws Michael
|
Nov/Dec 2022
Pg. 468-472
|
Pharmacogenomics as a Competitive Strategy for Compounding Pharmacies
Maham Nicole Y
|
Nov/Dec 2022
Pg. 474-479
|
A Compendium of Compounding Agents and Formulations, Part 6: Additional Preparations for Refractory Dermal-wound Healing
Riepl Mike
|
Nov/Dec 2022
Pg. 480-488
|
Compounding with Microneedle Arrays, Part 2: Preparation and Administration Methods
Allen Loyd V Jr
|
Nov/Dec 2022
Pg. 490-495
|
Sterile Basics of Compounding: Contamination Control Strategies, Part 2
Summers Amy
|
Nov/Dec 2022
Pg. 497-504
|
Calculations
Stockton Shelly J
|
Nov/Dec 2022
Pg. 506
|
Bacitracin 0.01% and Phenol 0.1% in Cetaphil Lotion
Allen Loyd V Jr
|
Nov/Dec 2022
Pg. 508
|
Curcumin 2% Topical Gel
Allen Loyd V Jr
|
Nov/Dec 2022
Pg. 509
|
Diazoxide 10-mg/mL in Oral Mix SF
Allen Loyd V Jr
|
Nov/Dec 2022
Pg. 510
|
Enrofloxacin 11.35 mg/mL in Ora-Blend, Veterinary
Allen Loyd V Jr
|
Nov/Dec 2022
Pg. 511
|
Flucytosine 50 mg/mL in Oral-Sweet and Ora-Plus
Allen Loyd V Jr
|
Nov/Dec 2022
Pg. 512
|
Granisetron Hydrochloride 005 mg/mL in Ora-Sweet and Ora-Plus
Allen Loyd V Jr
|
Nov/Dec 2022
Pg. 513
|
Miller's Modified Mouthwash
Allen Loyd V Jr
|
Nov/Dec 2022
Pg. 514
|
Potassium Alum 1% Bladder Irrigation for Hemorrhagic Cystitis (Low-Medium Risk Compounding)
Allen Loyd V Jr
|
Nov/Dec 2022
Pg. 515
|
Formulation Development of Modafinil Sprinkle Dosage Form: Study on the Effect of Food on Dosage
Kumaravelrajan Rajagopal, Karthik B, Venkatasan Suba
|
Nov/Dec 2022
Pg. 516-521
|
Intravenous Physical Compatibility of Heparin Sodium and Furosemide
Maktabi Briana, Howard Mitchell S, Baki Gabriella, Churchwell Mariann D
|
Nov/Dec 2022
Pg. 522-526
|
| Return to Top |
